India Glycols: Guidance on Cost of Acquisition Post Demerger

India Glycols Limited has issued a communication for its shareholders regarding the apportionment of the cost of acquisition for equity shares following a Scheme of Arrangement. The Scheme, sanctioned by the NCLT and effective from September 1, 2026, involved the demerger of Bio Pharma and Spirits & Biofuel Undertakings into Ennature Bio Pharma Limited (Resulting Company 1) and IGL Spirits Limited (Resulting Company 2). Shareholders received new equity shares in these resulting companies based on a specified ratio. The company provides guidance for shareholders to determine the proportionate cost of acquisition for their original India Glycols shares and the new shares in Ennature Bio Pharma and IGL Spirits, allocating 31.77% to India Glycols, 20.61% to Ennature Bio Pharma, and 47.62% to IGL Spirits. This guidance is for general information and shareholders are advised to consult tax advisors for specific implications.